Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

Cancer

Volumn 113, Issue 5, 2008, Pages 975-984

  Higano, Celestia S ^a,j   Corman, John M ^b   Smith, David C ^c   Centeno, Arthur S ^d   Steidle, Christopher P ^e   Gittleman, Marc ^f   Simons, Jonathan W ^g   Sacks, Natalie ^h   Aimi, Junko ^h   Small, Eric J ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d Urology San Antonio Research PA   (United States)

^e Northeast Indiana Urology   (United States)

^f South Florida Medical Research   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CELL GENESYS INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

more..

Author keywords

Clinical trial; Granulocyte macrophage colony stimulating factor; GVAX; Hormone refractory prostate cancer; Immunotherapy; Treatment

Indexed keywords

ANDROGEN; ANTIBODY; DOCETAXEL; GONADORELIN DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; CANCER VACCINE; TUMOR ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; KINETICS; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN SECRETION; RADIOLOGY; RASH; RIGOR; SIDE EFFECT; SUBDURAL HEMATOMA; SURVIVAL TIME; THROMBOCYTOPENIA; URTICARIA; WEIGHT REDUCTION; ADENOCARCINOMA; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; NEOPLASM; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 52049090425     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23669     Document Type: Article

References (21)

1. Sanda MG, Ayyagari SR, Jaffee EM. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151:622-628.
2. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13:3776-3782.
3. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12(11 pt 1):3394-3401.
4. Small EJ, Schellhammer PF, Higano CS, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
5. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006;24:434-441.
6. Dipaola R, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1.
7. Simmons AD, Li B, Gonzalez-Edick M, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007;56:1653-1665.
8. Small EJ, Sacks N, Nemunaitis J, et al. GM-CSF-secreting, allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883-3891.
9. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156.
10. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297-306.
11. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467. Erratum in: J Clin Oncol. 2000;18:2644.
12. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.
13. Agresti A. Categorical Data Analysis, New York: John Wiley; 1990:100-102.
14. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
15. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with HRPC. J Clin Oncol. 2003;21:1232-1237.
16. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337-6343.
17. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;15:1502-1512.
18. [Anonymous Author]. Leukine Sargramostim Package Insert, Revision 0230-03. Richmond, California: Berlex Laboratories; June 2002.
19. van der Flier A, Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta. 2001;1538:99-117.
20. Takafuta T, Wu G, Murphy GF, Shapiro SS. Human betafilamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. J Biol Chem. 1998;273:17531-17538.
21. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-274.